trending Market Intelligence /marketintelligence/en/news-insights/trending/CePvKcaZugrGHCaZUzHRSg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Cadila secures US FDA approval for epilepsy drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Cadila secures US FDA approval for epilepsy drug

Cadila Healthcare Ltd., under the aegis of Zydus Cadila, secured the U.S. Food and Drug Administration approval for Felbamate tablets.

The drug is used for the treatment of seizures in people with epilepsy.